

Zobair M Younossi

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/2066308/publications.pdf](https://exaly.com/author-pdf/2066308/publications.pdf)

Version: 2025-02-01

524

PR articles

81,050

PR citations

680

107

PR h-index

248

273

g-index

591

documents

89227

doc citations

925

112

h-index

50401

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Reply. Clinical Gastroenterology and Hepatology, 2024, 22, 430-432.	6.2	0
2	Reply. Clinical Gastroenterology and Hepatology, 2024, 22, 908.	6.2	0
3	Design of the phase 3 <scp>MAESTRO</scp> clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2024, 59, 51-63.	3.9	70
4	Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. Journal of Hepatology, 2024, 80, 419-430.	3.6	73
5	The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Hepatology Communications, 2024, 8, .	4.7	85
6	Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study. Hepatology Communications, 2024, 8, .	4.7	11
7	The impact of hepatitis B and C positive serologies on the outcomes of <scp>non-â€hepatic</scp> solid organ transplantation in the United States. Journal of Viral Hepatitis, 2024, 31, 181-188.	2.1	1
8	Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. Journal of Hepatology, 2024, 80, 694-701.	3.6	235
9	Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Liver International, 2024, 44, 1061-1070.	4.1	73
10	A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine, 2024, 390, 497-509.	43.7	1,346
11	Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action. Diabetes Spectrum, 2024, 37, 9-19.	1.2	54
12	Food Insecurity, Low Household Income, and Low Education Level Increase the Risk of Having Metabolic Dysfunction-associated Fatty Liver Disease Among Adolescents in the United States. American Journal of Gastroenterology, 2024, 119, 1089-1101.	0.7	41
13	Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease. Alimentary Pharmacology and Therapeutics, 2024, 59, 1183-1195.	3.9	10
14	The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clinical Gastroenterology and Hepatology, 2024, 22, 1999-2010.e8.	6.2	234
15	The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease. JHEP Reports, 2024, 6, 101066.	4.8	22
16	Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt. Journal of Viral Hepatitis, 2024, 31, 300-308.	2.1	4
17	Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis. Hepatology Communications, 2024, 8, .	4.7	16
18	Validation of a Primary Biliary Cholangitis-Specific Version of Chronic Liver Disease Questionnaire: CLDQ-PBC. Clinical and Translational Gastroenterology, 2024, 15, e1.	2.9	7

#	ARTICLE	IF	PR CITATIONS
19	MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials. <i>Journal of Internal Medicine</i> , 2024, 296, 24-38.	7.6	20
20	Review article: Hepatic steatosis and its associations with acute and chronic liver diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 60, 167-200.	3.9	15
21	Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis –prevalence, clinical impact, economic implications and management strategies. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, .	3.9	24
22	Liver Transplantation Profile Among Teenagers in the United States. <i>Journal of Adolescent Health</i> , 2024, 75, 578-583.	2.8	1
23	Estimating the economic impact of comorbidities in patients with MASH and defining high-cost burden in patients with noncirrhotic MASH. <i>Hepatology Communications</i> , 2024, 8, .	4.7	9
24	Alcohol and Metabolic Syndrome Interaction. <i>Clinics in Liver Disease</i> , 2024, 28, 601-620.	3.7	1
25	Changes in mortality due to Chronic Liver Diseases (CLD) during the COVID-19 pandemic: Data from the United States™ National Vital Statistics System. <i>PLoS ONE</i> , 2024, 19, e0289202.	2.4	4
26	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 90-102.e6.	6.2	21
27	The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 970-977.e1.	6.2	13
28	Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice. <i>JHEP Reports</i> , 2023, 5, 100596.	4.8	29
29	Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. <i>Gut</i> , 2023, 72, 581-589.	21.2	81
30	Securing wider EU commitment to the elimination of hepatitis C virus. <i>Liver International</i> , 2023, 43, 276-291.	4.1	12
31	Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 215-223.	3.9	17
32	Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 709-722.	3.9	50
33	Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. <i>Journal of Hepatology</i> , 2023, 78, 247-259.	3.6	164
34	A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 304-312.	3.9	29
35	The Growing Economic and Clinical Burden of Nonalcoholic Steatohepatitis (NASH) in the United States. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 454-467.	2.5	63
36	Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry, . <i>Journal of Viral Hepatitis</i> , 2023, 30, 335-344.	2.1	14

#	ARTICLE	IF	PR CITATIONS
37	Nonalcoholic Fatty Liver Disease Is Independently Associated With Higher All-Cause and Cause-Specific Mortality. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2588-2596.e3.	6.2	21
38	The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. <i>Hepatology</i> , 2023, 77, 1335-1347.	10.6	2,352
39	Nonalcoholic Fatty Liver Disease: Disease Burden and Disease Awareness. <i>Clinics in Liver Disease</i> , 2023, 27, 173-186.	3.7	27
40	Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC. <i>Hepatology Communications</i> , 2023, 7, e0049-e0049.	4.7	16
41	Sarcopenia Among Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Is Associated With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2876-2888.e5.	6.2	33
42	The use of current knowledge and noninvasive testing modalities for predicting at-risk nonalcoholic steatohepatitis and assessing fibrosis. <i>Liver International</i> , 2023, 43, 964-974.	4.1	17
43	Letter: should we abandon <scp>FIB</scp> to characterise noninvasively patients with <scp>NAFLD</scp>? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 922-923.	3.9	0
44	The combination of the enhanced liver fibrosis and FIB scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 1417-1422.	3.9	9
45	Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties. <i>Journal of Hepatology</i> , 2023, 79, 209-217.	3.6	118
46	Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.). <i>Annals of Hepatology</i> , 2023, 28, 101108.	1.6	9
47	The Global Burden of Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1978-1991.	6.2	371
48	Lifestyle interventions in nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 708-722.	48.0	212
49	Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics. <i>Endocrine Practice</i> , 2023, 29, 912-918.	3.5	11
50	Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplantations in the U.S.: Data From a National Registry. <i>Diabetes Care</i> , 2023, 46, 2162-2170.	6.5	13
51	Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience. <i>Clinical Infectious Diseases</i> , 2022, 74, 1063-1069.	5.4	69
52	Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1354-1361.e7.	6.2	68
53	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.	6.2	98
54	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2050-2058.e12.	6.2	80

#	ARTICLE	IF	PR CITATIONS
55	Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data. <i>Hepatology Communications</i> , 2022, 6, 90-100.	4.7	43
56	Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID-19 Infection. <i>Hepatology Communications</i> , 2022, 6, 3062-3072.	4.7	48
57	Liver Transplant Center Size and the Impact on Clinical Outcomes and Resource Utilization. <i>Transplantation</i> , 2022, 106, 988-996.	1.2	13
58	Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1149-e1156.	6.2	4
59	Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 438-446.	6.2	17
60	The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2915-2917.e1.	6.2	14
61	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	10.6	125
62	Global burden of NAFLD and chronic liver disease among adolescents and young adults. <i>Hepatology</i> , 2022, 75, 1204-1217.	10.6	205
63	Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C. <i>Annals of Hepatology</i> , 2022, 27, 100556.	1.6	64
64	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2022, 76, 536-548.	3.6	137
65	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2022, 162, 680-688.	1.0	98
66	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2296-2306.e6.	6.2	88
67	Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2022, , .	0.7	74
68	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041.	3.6	136
69	Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis. <i>Endocrine Practice</i> , 2022, 28, 204-213.	3.5	27
70	Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients. <i>Hepatology Communications</i> , 2022, 6, 1506-1515.	4.7	58
71	Outcomes of hospitalized patients with COVID-19 during the course of the pandemic in a fully integrated health system. <i>PLoS ONE</i> , 2022, 17, e0263417.	2.4	7
72	Interrelationship between physical activity and depression in nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2022, 14, 612-622.	2.3	12

#	ARTICLE	IF	PR CITATIONS
73	Health-Related Quality of Life and Health Care Resource Utilization in Patients With Chronic Liver Disease and Primary Liver Cancer in the United States: Analysis of Medical Expenditure Panel Survey. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 272-277.	2.5	4
74	Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?. <i>Hepatology</i> , 2022, 76, 1423-1437.	10.6	162
75	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	3.6	219
76	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	10.6	45
77	Service line care delivery model for COVID-19 patient-centric care. <i>American Journal of Managed Care</i> , 2022, 28, e80-e87.	1.1	4
78	Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. <i>Hepatology Communications</i> , 2022, 6, 765-779.	4.7	70
79	Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999-2016. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2838-2847.e7.	6.2	63
80	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. <i>Endocrine Practice</i> , 2022, 28, 528-562.	3.5	818
81	The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. <i>JHEP Reports</i> , 2022, 4, 100525.	4.8	72
82	Association of Previous Gastric Bypass Surgery and Patient Outcomes in Alcohol-Associated Cirrhosis Hospitalizations. <i>Digestive Diseases and Sciences</i> , 2022, 68, 1026-1034.	2.3	9
83	Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 942-956.	3.9	181
84	The impact of the COVID-19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry. <i>Hepatology Communications</i> , 2022, 6, 2860-2866.	4.7	6
85	Sarcopenia, healthy living, and mortality in patients with chronic liver diseases. <i>Hepatology Communications</i> , 2022, 6, 3140-3153.	4.7	27
86	Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry. <i>Journal of Viral Hepatitis</i> , 2022, 29, 1015-1025.	2.1	7
87	The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005-2010 and 2017-2018. <i>Liver International</i> , 2022, 42, 2646-2661.	4.1	28
88	Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 580-589.e5.	6.2	487
89	Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 629-636.	2.7	39
90	Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1240-1247.e5.	6.2	71

#	ARTICLE	IF	PR CITATIONS
91	Health-related quality of life in Cuban patients with chronic liver disease: A real-world experience. <i>Annals of Hepatology</i> , 2021, 22, 100277.	1.6	23
92	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021, 160, 1608-1619.e13.	1.0	100
93	Integrating Patient-Reported Outcomes Within Routine Hepatology Care: A Prompt to Action. <i>Hepatology</i> , 2021, 73, 1570-1580.	10.6	14
94	AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. <i>Gastroenterology</i> , 2021, 160, 912-918.	1.0	423
95	Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV. <i>Journal of Viral Hepatitis</i> , 2021, 28, 484-492.	2.1	24
96	NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , 2021, 73, 2028-2038.	10.6	140
97	Major Histocompatibility Complex Class I-Related Chain A Alleles and Histology of Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2021, 5, 63-73.	4.7	5
98	Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2021, 31, 2002-2010.	2.4	31
99	Recent Trends in the Global Burden of Hepatitis B Virus: 2007-2017. <i>Gastroenterology</i> , 2021, 160, 1845-1846.e3.	1.0	21
100	Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00340.	2.9	19
101	Hospice care utilisation among elderly patients who died with hepatocellular carcinoma in the United States. <i>JHEP Reports</i> , 2021, 3, 100236.	4.8	11
102	Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2021, 5, 1201-1211.	4.7	29
103	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , 2021, 74, 133-147.	10.6	169
104	Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100280.	4.8	18
105	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1299-1300.	6.2	2
106	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 717-729.	48.0	119
107	Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021, 44, 2162-2172.	6.5	42
108	Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007-2016. <i>Hepatology Communications</i> , 2021, 5, 1676-1688.	4.7	71

#	ARTICLE	IF	PR CITATIONS
109	Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. <i>Hepatology Communications</i> , 2021, 5, 1833-1847.	4.7	102
110	The impact of hepatocellular carcinoma diagnosis on patients' health-related quality of life. <i>Cancer Medicine</i> , 2021, 10, 6273-6281.	2.7	14
111	Association between Activity and Brain-Derived Neurotrophic Factor in Patients with Non-Alcoholic Fatty Liver Disease: A Data-Mining Analysis. <i>Life</i> , 2021, 11, 799.	2.8	10
112	Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. <i>JHEP Reports</i> , 2021, 3, 100305.	4.8	138
113	Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021, 29, 1401-1412.	4.2	13
114	Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1239-1248.	1.2	7
115	Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021, 161, 1030-1042.e8.	1.0	96
116	Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154822.	9.5	36
117	Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2021, 4, e2123923.	6.8	57
118	Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. <i>Journal of Hepatology</i> , 2021, 75, 795-809.	3.6	218
119	The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. <i>Hepatology Communications</i> , 2021, 5, 749-759.	4.7	39
120	Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. <i>American Journal of Gastroenterology</i> , 2021, 116, 254-262.	0.7	94
121	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 19, 60-78.	48.0	608
122	Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes. <i>Clinical Infectious Diseases</i> , 2020, , .	5.4	9
123	Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 468-476.e11.	6.2	21
124	Epidemiology of chronic liver diseases in the USA in the past three decades. <i>Gut</i> , 2020, 69, 564-568.	21.2	461
125	Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes. <i>Liver International</i> , 2020, 40, 308-318.	4.1	6
126	Genecriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	1.6	120

#	ARTICLE	IF	PR CITATIONS
127	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	4.1	32
128	The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 291-304.	3.9	51
129	Increased cancer rates in patients with chronic hepatitis C. <i>Liver International</i> , 2020, 40, 685-693.	4.1	28
130	Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 459-467.	2.4	54
131	Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. <i>Hepatology Communications</i> , 2020, 4, 1136-1148.	4.7	89
132	Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. <i>American Journal of Gastroenterology</i> , 2020, 115, 1496-1504.	0.7	65
133	Abnormal cardiac and metabolic measures correlate significantly with lower performance and activity in overweight chronic liver disease. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1915-1923.	2.2	1
134	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. <i>Hepatology Communications</i> , 2020, 4, 1637-1650.	4.7	51
135	Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians. <i>Journal of Hepatology</i> , 2020, 73, S440.	3.6	4
136	The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017. <i>Hepatology Communications</i> , 2020, 4, 1769-1780.	4.7	88
137	Decline in Annual Mortality of Hepatitis C Virus-Related Hepatocellular Carcinoma in the United States, From 2009 to 2018. <i>Gastroenterology</i> , 2020, 159, 1558-1560.e2.	1.0	26
138	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020, 50, 1024-1031.	3.1	44
139	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020, 73, 26-39.	3.6	419
140	Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 513-526.	3.9	86
141	Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. <i>Hepatology</i> , 2020, 72, 1605-1616.	10.6	684
142	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	1.0	2,797
143	Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.. <i>Diabetes Care</i> , 2020, 43, 283-289.	6.5	145
144	Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006-2016. <i>Open Forum Infectious Diseases</i> , 2020, 7, .	0.8	16

#	ARTICLE	IF	PR CITATIONS
145	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.	1.0	895
146	Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States. <i>Hepatology Communications</i> , 2020, 4, 890-903.	4.7	72
147	Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population. <i>Hepatology International</i> , 2020, 14, 556-566.	4.5	39
148	Gamma glutamyltransferase and risk of dementia in prediabetes and diabetes. <i>Scientific Reports</i> , 2020, 10, .	3.5	17
149	Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2020, 2, 100171.	4.8	107
150	Epidemiology of Non-alcoholic Fatty Liver Disease in North America. <i>Current Pharmaceutical Design</i> , 2020, 26, 993-997.	2.4	60
151	Management of nonalcoholic fatty liver disease in the Middle East. <i>World Journal of Gastroenterology</i> , 2020, 26, 3528-3541.	4.8	22
152	Outcomes of liver transplantation by insurance types in the United States. <i>American Journal of Managed Care</i> , 2020, 26, e121-e126.	1.1	40
153	Letter: the use of Fibrosisâ€4 score in primary care and diabetology practicesâ€”Occam's razor applied to advanced fibrosis screening. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1761-1761.	3.9	0
154	Viral eradication is required for sustained improvement of patientâ€reported outcomes in patients with hepatitis C. <i>Liver International</i> , 2019, 39, 54-59.	4.1	28
155	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.	6.2	710
156	Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis. <i>Liver Transplantation</i> , 2019, 25, 68-78.	2.6	26
157	Primary Biliary Cholangitis in Medicare Population. <i>Hepatology</i> , 2019, 69, 237-244.	10.6	23
158	Changing Trends in Etiologyâ€Based and Ethnicityâ€Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2019, 69, 1064-1074.	10.6	179
159	Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Haemodialysis units. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1293-1300.	2.1	6
160	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803.	1.6	117
161	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.	10.6	247
162	The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 793-801.	3.6	1,898

#	ARTICLE	IF	PR CITATIONS
163	Hepatocellular carcinoma and non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2019, 13, 688-694.	4.5	66
164	Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. <i>Hepatology Communications</i> , 2019, 3, 1459-1471.	4.7	199
165	Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study. <i>Journal of Neuroimmunology</i> , 2019, 335, 577022.	2.4	11
166	“ Mortality Related to Non-Alcoholic Fatty Liver Disease is Increasing in the United States Over the Last Decade. <i>Gastroenterology</i> , 2019, 156, S-1253.	1.0	1
167	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2383-2384.	6.2	1
168	A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia. <i>Hematology</i> , 2019, 24, 679-719.	1.4	20
169	Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States. <i>Hepatology Communications</i> , 2019, 3, 356-364.	4.7	16
170	Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005–2016. <i>Hepatology International</i> , 2019, 13, 205-213.	4.5	82
171	Reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. <i>Liver International</i> , 2019, 39, 1837-1844.	4.1	27
172	Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2019, 3, 1050-1060.	4.7	58
173	Trends in hospitalizations for chronic liver disease–related liver failure in the United States, 2005–2014. <i>Liver International</i> , 2019, 39, 1661-1671.	4.1	41
174	Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. <i>BMC Gastroenterology</i> , 2019, 19, .	2.4	103
175	Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2093-2100.e3.	6.2	44
176	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2552-2560.e10.	6.2	79
177	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019, 70, 1913-1927.	10.6	337
178	Resource Utilization and Outcomes of Medicare Recipients With Chronic Hepatitis B in the United States. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e341-e347.	2.4	2
179	Disease Burden of Hepatocellular Carcinoma: A Global Perspective. <i>Digestive Diseases and Sciences</i> , 2019, 64, 910-917.	2.3	290
180	Cytokine balance is restored as patient–reported outcomes improve in patients recovering from chronic hepatitis C. <i>Liver International</i> , 2019, 39, 1631-1640.	4.1	7

#	ARTICLE	IF	PR CITATIONS
181	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	6.2	156
182	Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2019, 19, .	2.4	17
183	Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 644-653.	3.9	32
184	Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. <i>American Journal of Gastroenterology</i> , 2019, 114, 1636-1641.	0.7	48
185	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	52.8	1,092
186	Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease. <i>Medicine (United States)</i> , 2019, 98, e16704.	1.3	11
187	A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 331-341.	2.4	36
188	Implementation of Value-based Medicine (VBM) to Patients With Chronic Hepatitis C (HCV) Infection. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 262-268.	2.4	4
189	Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States. <i>Hepatology</i> , 2019, 69, 564-572.	10.6	190
190	Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 69, 2672-2682.	10.6	1,628
191	Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 693-698.	2.4	13
192	Long-term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1641-1642.e1.	6.2	15
193	Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. <i>Liver International</i> , 2019, 39, 748-757.	4.1	55
194	Non-alcoholic fatty liver disease – A global public health perspective. <i>Journal of Hepatology</i> , 2019, 70, 531-544.	3.6	1,890
195	Diagnosis and Management of Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 48-63.	0.7	176
196	Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population. <i>Hepatology Communications</i> , 2019, 3, 74-83.	4.7	50
197	Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 342-352.	4.1	50
198	Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 332-341.	4.1	50

#	ARTICLE	IF	PR CITATIONS
199	Nonalcoholic Fatty Liver is Contributing to the Increase in Cases of Liver Disease in US Emergency Departments. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 58-64.	2.4	3
200	Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. <i>Journal of Gastroenterology</i> , 2019, 55, 330-341.	4.5	23
201	Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients. <i>Digestive Diseases and Sciences</i> , 2019, 65, 416-422.	2.3	9
202	Aerobic capacity and exercise performance in nonalcoholic fatty liver disease. <i>Journal of Sports Medicine and Physical Fitness</i> , 2019, 59, .	1.1	22
203	Importance of fatigue and its measurement in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 3669-3683.	4.8	71
204	Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. <i>Quality of Life Research</i> , 2018, 27, 1513-1520.	2.1	39
205	Quality of Life in Patients with Cirrhosis—Measurement and Clinical Impact. <i>Current Hepatology Reports</i> , 2018, 17, 15-21.	0.7	2
206	Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. <i>Journal of Viral Hepatitis</i> , 2018, 25, 811-817.	2.1	29
207	Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the <scp>TRIO</scp> network. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1511-1522.	3.9	29
208	The Stomach as an Endocrine Organ: Expression of Key Modulatory Genes and Their Contribution to Obesity and Non-alcoholic Fatty Liver Disease (NAFLD). <i>Current Gastroenterology Reports</i> , 2018, 20, .	2.7	5
209	Patient-Reported Outcomes for Patients With Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 793-799.	6.2	16
210	Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 965-973.e2.	6.2	30
211	Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. <i>Liver International</i> , 2018, 38, 1849-1859.	4.1	82
212	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation. <i>Liver Transplantation</i> , 2018, 24, 166-170.	2.6	64
213	Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 567-574.e6.	6.2	27
214	Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 680-688.	3.9	18
215	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. <i>Clinical Infectious Diseases</i> , 2018, 66, 1742-1750.	5.4	23
216	Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens. <i>Journal of Infectious Diseases</i> , 2018, 217, 1033-1043.	3.8	24

#	ARTICLE	IF	PR CITATIONS
217	The epidemiology of nonalcoholic steatohepatitis. <i>Clinical Liver Disease</i> , 2018, 11, 92-94.	1.4	82
218	Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1641-1649.e6.	6.2	36
219	Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). <i>Medicine (United States)</i> , 2018, 97, e0214.	1.3	189
220	Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. <i>Journal of Viral Hepatitis</i> , 2018, 25, 945-951.	2.1	20
221	In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. <i>Liver International</i> , 2018, 38, 258-265.	4.1	36
222	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 67, 328-357.	10.6	6,141
223	Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 123-128.	3.9	14
224	Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. <i>Journal of Viral Hepatitis</i> , 2018, 25, 228-235.	2.1	12
225	Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 452-453.	6.2	36
226	Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2018, 22, 1-10.	3.7	105
227	Waist-to-calf circumference ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1082-1091.	2.7	25
228	The efficacy of new antiviral regimens for hepatitis C infection: Evidence from a systematic review. <i>Hepatology</i> , 2018, 67, 1160-1162.	10.6	3
229	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. <i>Hepatology</i> , 2018, 68, 349-360.	10.6	377
230	Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Hepatology</i> , 2018, 68, 361-371.	10.6	313
231	Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV). <i>Value in Health</i> , 2018, 21, 612-621.	2.0	9
232	Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 259-267.	3.9	42
233	Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. <i>Journal of Viral Hepatitis</i> , 2018, 25, 354-362.	2.1	26
234	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018, 38, 1179-1187.	4.1	18

#	ARTICLE	IF	PR CITATIONS
235	Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument. <i>Hepatology</i> , 2018, 68, 155-165.	10.6	37
236	Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. <i>Hepatology</i> , 2018, 67, 123-133.	10.6	2,094
237	Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. <i>Annals of Hepatology</i> , 2018, 17, 11-13.	1.6	4
238	Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis. <i>Medicine (United States)</i> , 2018, 97, e11518.	1.3	69
239	Exercise as an intervention for patients with end-stage liver disease. <i>Medicine (United States)</i> , 2018, 97, e12774.	1.3	20
240	Association of Parity in Patients with Chronic Liver Disease. <i>Annals of Hepatology</i> , 2018, 17, 1035-1041.	1.6	7
241	Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, .	3.5	17
242	Impact of Chronic Hepatitis B Infection on Patient-Reported Outcomes. <i>Current Hepatology Reports</i> , 2018, 17, 459-465.	0.7	0
243	The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. <i>Journal of Viral Hepatitis</i> , 2018, 25, 6-14.	2.1	32
244	Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. <i>Hepatology Communications</i> , 2018, 2, 1227-1234.	4.7	25
245	Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey. <i>PLoS ONE</i> , 2018, 13, e0204772.	2.4	28
246	The Clinical and Economic Burden of Nonalcoholic Steatohepatitis. <i>Current Hepatology Reports</i> , 2018, 17, 345-349.	0.7	5
247	An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease. <i>BMC Medicine</i> , 2018, 16, .	7.5	14
248	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1140-1153.	1.0	335
249	559 - Factors Associated with Progressive Course of Patients with Primary Biliary Cholangitis in the United States: Data from a Large-Real World Database. <i>Gastroenterology</i> , 2018, 154, S-1097.	1.0	1
250	Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH). <i>PLoS ONE</i> , 2018, 13, e0199294.	2.4	22
251	Response to the letter: Hepatitis C screening in opioid epidemics in the United States and societal perspectives. <i>Liver International</i> , 2018, 38, 1331-1331.	4.1	0
252	Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition. <i>Hepatology</i> , 2018, 68, 2405-2412.	10.6	51

#	ARTICLE	IF	PR CITATIONS
253	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1429-1437.	2.1	17
254	Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1608-1616.	2.1	18
255	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018, 69, 1365-1370.	3.6	71
256	Cognitive Performance in Individuals With Non-Alcoholic Fatty Liver Disease and/or Type 2 Diabetes Mellitus. <i>Psychosomatics</i> , 2018, 59, 567-574.	3.0	44
257	Chronic kidney disease in patients with chronic hepatitis C virus infection. <i>Minerva Gastroenterologica E Dietologica</i> , 2018, 64, .	0.7	2
258	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , 2017, 65, 1557-1565.	10.6	1,674
259	The epidemiologic characteristics, temporal trends, predictors of death, and discharge disposition in patients with a diagnosis of sepsis: A cross-sectional retrospective cohort study. <i>Journal of Critical Care</i> , 2017, 39, 48-55.	2.4	14
260	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	3.6	80
261	A disease-specific quality of life instrument for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: <scp>CLDQ</scp> <scp>NAFLD</scp>. <i>Liver International</i> , 2017, 37, 1209-1218.	4.1	97
262	Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States. <i>Journal of Viral Hepatitis</i> , 2017, 24, 789-796.	2.1	16
263	Hepatitis C virus infection. <i>Nature Reviews Disease Primers</i> , 2017, 3, .	50.7	450
264	Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials. <i>Health and Quality of Life Outcomes</i> , 2017, 15, .	3.0	19
265	Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. <i>Hepatology</i> , 2017, 66, 46-56.	10.6	27
266	Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1087-1094.e2.	6.2	24
267	Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 449-453.	3.7	28
268	Economic Burden of Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 579-594.	3.7	64
269	Patient-reported outcomes in patients coinfected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. <i>Liver International</i> , 2017, 37, 1796-1804.	4.1	32
270	Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2174-2181.	2.3	24

#	ARTICLE	IF	PR CITATIONS
271	Patient-Reported Outcomes and Fatigue in Patients with Chronic Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 565-578.	3.7	37
272	Hepatitis C Virus Infection Care Pathway—A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. <i>Gastroenterology</i> , 2017, 152, 1588-1598.	1.0	10
273	The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?. <i>Liver International</i> , 2017, 37, 662-668.	4.1	16
274	Dermatologic Manifestations of Chronic Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 555-564.	3.7	29
275	Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. <i>Journal of Hepatology</i> , 2017, 67, 940-949.	3.6	107
276	Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1144-1147.	6.2	31
277	Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). <i>Patient</i> , 2017, 10, 605-614.	2.3	4
278	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	7.5	96
279	Demographics, Resource Utilization, and Outcomes of Elderly Patients With Chronic Liver Disease Receiving Hospice Care in the United States. <i>American Journal of Gastroenterology</i> , 2017, 112, 1700-1708.	0.7	24
280	Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2695-2706.	3.2	28
281	Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 540-548.	3.9	37
282	Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2915-2922.	2.3	213
283	Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2017, 21, 739-753.	3.7	36
284	Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2017, 1, 421-428.	4.7	116
285	Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. <i>Medicine (United States)</i> , 2017, 96, e5904.	1.3	223
286	Superiority of Interferon-Free Regimens for Chronic Hepatitis C. <i>Medicine (United States)</i> , 2017, 96, e5914.	1.3	44
287	Demonstration of two types of fatigue in subjects with chronic liver disease using factor analysis. <i>Quality of Life Research</i> , 2017, 26, 1777-1784.	2.1	14
288	The impact of hepatitis C virus outside the liver: Evidence from Asia. <i>Liver International</i> , 2017, 37, 159-172.	4.1	41

#	ARTICLE	IF	PR CITATIONS
289	Direct and Indirect Economic Burden of Chronic Liver Disease in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 759-766.e5.	6.2	143
290	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 421-430.e6.	6.2	76
291	Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 254-260.	2.4	71
292	Fatigue and Hepatitis C: a focus group study. <i>Qualitative Research in Medicine & Healthcare</i> , 2017, 1, .	0.3	4
293	Pediatric Non-Alcoholic Fatty Liver Disease. <i>Children</i> , 2017, 4, 48.	1.7	54
294	Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2017, 16, 555-564.	1.6	20
295	The Prevalence of Parkinson Disease Among Patients With Hepatitis C Infection. <i>Annals of Hepatology</i> , 2017, 16, 342-348.	1.6	12
296	Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 15, 11-20.	48.0	4,698
297	Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2017, .	2.3	8
298	Trends in Liver Transplantation in Hepatitis C Virus-Infected Persons, United States. <i>Emerging Infectious Diseases</i> , 2016, 22, 565-567.	3.9	2
299	Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. <i>World Journal of Gastroenterology</i> , 2016, 22, 6318.	4.8	155
300	Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States. <i>Medicine (United States)</i> , 2016, 95, e2482.	1.3	13
301	Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon and Ribavirin-Free Regimens. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 386-393.	2.9	37
302	The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the <sc>SIRIUS</sc> study. <i>Liver International</i> , 2016, 36, 42-48.	4.1	52
303	Vaccination against hepatitis A and B in patients with chronic liver disease and type 2 diabetes: has anything changed?. <i>Liver International</i> , 2016, 36, 1096-1100.	4.1	9
304	Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. <i>Medicine (United States)</i> , 2016, 95, e2702.	1.3	34
305	Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic <sc>HCV</sc> genotype 1-infected treatment-naïve patients. <i>Liver International</i> , 2016, 36, 189-197.	4.1	26
306	An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. <i>American Journal of Gastroenterology</i> , 2016, 111, 808-816.	0.7	86

#	ARTICLE	IF	PR CITATIONS
307	Nonalcoholic Steatohepatitis and Liver Transplantation. <i>Current Hepatology Reports</i> , 2016, 15, 113-116.	0.7	1
308	Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2505-2515.	2.3	12
309	The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). <i>BMC Medical Genetics</i> , 2016, 17, .	2.0	32
310	Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 122-132.	23.6	70
311	Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 659-665.	1.5	6
312	Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. <i>Value in Health</i> , 2016, 19, 544-551.	2.0	46
313	The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. <i>Hepatology</i> , 2016, 64, 1577-1586.	10.6	1,110
314	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.	7.5	96
315	Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 1042-1048.	5.4	57
316	Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. <i>Liver Transplantation</i> , 2016, 22, 1356-1366.	2.6	24
317	Long-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry. <i>Clinical Transplantation</i> , 2016, 30, 1570-1577.	1.7	22
318	Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000096.	2.6	49
319	Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000106.	2.6	70
320	Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. <i>BMC Gastroenterology</i> , 2016, 16, .	2.4	27
321	The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV). <i>Medicine (United States)</i> , 2016, 95, e5066.	1.3	7
322	Adherence to treatment of chronic hepatitis C. <i>Medicine (United States)</i> , 2016, 95, e4151.	1.3	70
323	Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. <i>Medicine (United States)</i> , 2016, 95, e4243.	1.3	14
324	Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States. <i>Medicine (United States)</i> , 2016, 95, e5048.	1.3	32

#	ARTICLE	IF	PR CITATIONS
325	Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology</i> , 2016, 64, 73-84.	10.6	9,456
326	603 Access to Therapy in Era of All DAA Regimens: Real-World Experience From the TRIO Network. <i>Gastroenterology</i> , 2016, 150, S1040.	1.0	1
327	Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study. <i>BMC Gastroenterology</i> , 2016, 16, .	2.4	20
328	Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). <i>Health and Quality of Life Outcomes</i> , 2016, 14, .	3.0	128
329	Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies. <i>Health and Quality of Life Outcomes</i> , 2016, 14, .	3.0	2
330	Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity. <i>Psychosomatics</i> , 2016, 57, 82-88.	3.0	20
331	Epidemiology and natural history of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1017-1025.	9.5	389
332	Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. <i>Gastroenterology</i> , 2016, 150, 1778-1785.	1.0	303
333	Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. <i>Gastroenterology</i> , 2016, 150, 1599-1608.	1.0	353
334	Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. <i>Journal of Hepatology</i> , 2016, 65, 33-39.	3.6	105
335	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. <i>Clinics in Liver Disease</i> , 2016, 20, 205-214.	3.7	478
336	Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 156-164.e3.	6.2	58
337	Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. <i>Journal of Hepatology</i> , 2016, 64, 29-36.	3.6	32
338	Perception of Effort During Activity in Patients With Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease. <i>PM and R</i> , 2016, 8, 28-34.	2.0	13
339	Underutilization of Living Donor Liver Transplantation in the United States: Bias against MELD 20 and Higher. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 169-174.	2.3	9
340	Treatment strategies for chronic hepatitis C prior to and following liver transplantation. <i>World Journal of Hepatology</i> , 2016, 8, 69.	2.3	10
341	Reply to “Debilitating fatigue as a treatment indication in chronic hepatitis C”. <i>Journal of Hepatology</i> , 2015, 63, 1534-1535.	3.6	1
342	Overall health-related quality of life in patients with end-stage liver disease. <i>Clinical Liver Disease</i> , 2015, 6, 9-14.	1.4	30

#	ARTICLE	IF	PR CITATIONS
343	The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving?. <i>Clinical Liver Disease</i> , 2015, 6, 126-128.	1.4	3
344	Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2015, 15, .	2.4	29
345	Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. <i>Hepatology</i> , 2015, 62, 1723-1730.	10.6	737
346	The outcomes of adult liver transplants in the United States from 1987 to 2013. <i>Liver International</i> , 2015, 35, 2036-2041.	4.1	32
347	<sc>HCV</sc> infection is associated with lower survival in simultaneous liver kidney transplant recipients in the United States. <i>Clinical Transplantation</i> , 2015, 29, 920-926.	1.7	7
348	Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. <i>Hepatology</i> , 2015, 61, 1471-1478.	10.6	46
349	What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?. <i>Clinical Liver Disease</i> , 2015, 6, 117-119.	1.4	8
350	Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION1, 2, and 3 clinical trials. <i>Hepatology</i> , 2015, 61, 1798-1808.	10.6	129
351	Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. <i>Gastroenterology</i> , 2015, 148, 547-555.	1.0	1,677
352	Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced <sc>HCV</sc> genotype 1 patients: <sc>REALIZE</sc> study. <i>Liver International</i> , 2015, 35, 448-454.	4.1	6
353	Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. <i>Journal of Infectious Diseases</i> , 2015, 212, 367-377.	3.8	55
354	Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease. <i>Pharmacoeconomics</i> , 2015, 33, 1245-1253.	3.7	84
355	The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 298-312.	3.5	93
356	A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Hepatology</i> , 2015, 62, 1204-1206.	3.6	52
357	Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3248-3251.	2.3	26
358	Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. <i>Journal of Hepatology</i> , 2015, 63, 337-345.	3.6	154
359	Trends in Outpatient Resource Utilizations and Outcomes for Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 222-227.	2.4	47
360	Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 900-908.	2.7	7

#	ARTICLE	IF	PR CITATIONS
361	Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study. <i>Annals of Medicine</i> , 2015, 47, 40-46.	4.1	42
362	Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD. <i>Liver International</i> , 2015, 35, 1367-1372.	4.1	25
363	Predictors of chronic liver disease in individuals with human immunodeficiency virus infection. <i>Annals of Hepatology</i> , 2014, 13, 60-64.	1.6	9
364	Survey of health status, nutrition and geography of food selection of chronic liver disease patients. <i>Annals of Hepatology</i> , 2014, 13, 533-540.	1.6	27
365	Statin use is not associated with liver related mortality. <i>Annals of Hepatology</i> , 2014, 13, 84-90.	1.6	13
366	Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects. <i>BMC Gastroenterology</i> , 2014, 14, .	2.4	32
367	Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. <i>BMJ Open</i> , 2014, 4, e004318.	2.0	31
368	A single non-invasive model to diagnose non-alcoholic fatty liver disease (<scp>NAFLD</scp>) and non-alcoholic steatohepatitis (<scp>NASH</scp>). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 2006-2013.	2.7	85
369	Markers of endothelial dysfunction in patients with non-alcoholic fatty liver disease and coronary artery disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1528-1534.	2.7	22
370	Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. <i>Hepatology</i> , 2014, 59, 2161-2169.	10.6	79
371	Multiple Factors Predict Physical Performance in People with Chronic Liver Disease. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2014, 93, 470-476.	1.5	20
372	The Portrait of an Adult Liver Transplant Recipient in the United States From 1987 to 2013. <i>JAMA Internal Medicine</i> , 2014, 174, 1407.	10.8	40
373	Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. <i>Journal of Hepatology</i> , 2014, 61, 228-234.	3.6	90
374	Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1349-1359.e13.	6.2	88
375	Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). <i>Journal of Hepatology</i> , 2014, 60, 741-747.	3.6	90
376	Obesity-Associated Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 19-31.	3.7	86
377	Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. <i>Journal of Hepatology</i> , 2014, 60, 530-537.	3.6	118
378	Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. <i>Lancet, The</i> , 2014, 384, 1756-1765.	52.8	769

#	ARTICLE	IF	PR CITATIONS
379	Hepatitis C Virus Infection and Coronary Artery Disease Risk: A Systematic Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1586-1593.	2.3	51
380	Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2014, 14, .	2.4	7
381	Host Genetic Variants in Obesity-Related Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 249-267.	3.7	11
382	Adipose Tissue as an Endocrine Organ. <i>Clinics in Liver Disease</i> , 2014, 18, 41-58.	3.7	173
383	A New Comorbidity Model for Predicting Mortality in Patients With Cirrhosis: Does It Work?. <i>Gastroenterology</i> , 2014, 146, 19-24.	1.0	9
384	Inpatient Economic and Mortality Assessment for Liver Transplantation. <i>Transplantation</i> , 2014, 97, 98-103.	1.2	19
385	Resource Utilization and Survival Among Medicare Patients with Advanced Liver Disease. <i>Digestive Diseases and Sciences</i> , 2014, 60, 320-332.	2.3	10
386	Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS). <i>Journal of Translational Medicine</i> , 2013, 11, .	6.6	78
387	Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Digestive Diseases and Sciences</i> , 2013, 58, 3017-3023.	2.3	272
388	Association of Sleep Disorders with Nonalcoholic Fatty Liver Disease (NAFLD): A Population-based Study. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 181-185.	2.5	50
389	Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 488-494.	3.6	19
390	Expression of genes for microRNA processing enzymes is altered in advanced non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1410-1415.	2.7	37
391	Comparison of activity level among patients with chronic liver disease. <i>Disability and Rehabilitation</i> , 2013, 35, 907-912.	2.6	10
392	In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 352-360.	9.5	162
393	Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 883-889.	3.6	52
394	Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. <i>Hepatology</i> , 2013, 58, 1897-1906.	10.6	21
395	Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1878-1887.	43.7	1,651
396	Association of Chronic Liver Disease with Depression: A Population-Based Study. <i>Psychosomatics</i> , 2013, 54, 52-59.	3.0	93

#	ARTICLE	IF	PR CITATIONS
397	Interaction of Type 2 diabetes and nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2013, 7, 405-407.	2.5	10
398	Expression of Inflammation-Related Genes Is Altered in Gastric Tissue of Patients with Advanced Stages of NAFLD. Mediators of Inflammation, 2013, 2013, 1-10.	3.8	5
399	The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample. Liver International, 2013, 33, 1281-1286.	4.1	31
400	Current management of patients with nonalcoholic fatty liver disease. Expert Review of Endocrinology and Metabolism, 2013, 8, 549-558.	3.1	3
401	Validation of the chronic liver disease questionnaire in Serbian patients. World Journal of Gastroenterology, 2013, 19, 4950.	4.8	17
402	Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example. PLoS ONE, 2013, 8, e56009.	2.4	15
403	Oral L-Ornithine-L-Aspartate Improves Health-Related Quality of Life in Cirrhotic Patients with Hepatic Encephalopathy. Clinical Drug Investigation, 2012, 31, 213-220.	2.2	31
404	The Intestinal Microbiota and Liver Disease. American Journal of Gastroenterology Supplements (Print), 2012, 1, 9-14.	1.5	46
405	Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States. Medicine (United States), 2012, 91, 319-327.	1.3	477
406	African Americans Are Less Likely to Have Clearance of Hepatitis C Virus Infection. Journal of Clinical Gastroenterology, 2012, 46, e62-e65.	2.4	18
407	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 2012, 142, 1592-1609.	1.0	1,655
408	Independent Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in the US Population. Clinical Gastroenterology and Hepatology, 2012, 10, 646-650.	6.2	318
409	Natural history of nonalcoholic fatty liver disease. Clinical Liver Disease, 2012, 1, 112-113.	1.4	8
410	In-Hospital Mortality and Economic Burden Associated With Hepatic Encephalopathy in the United States From 2005 to 2009. Clinical Gastroenterology and Hepatology, 2012, 10, 1034-1041.e1.	6.2	207
411	Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology, 2012, 2, 135-144.	2.5	76
412	Disparities in Activity Level and Nutrition Between Patients With Chronic Hepatitis C and Blood Donors. PM and R, 2012, 4, 436-441.	2.0	4
413	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. American Journal of Gastroenterology, 2012, 107, 811-826.	0.7	381
414	Economic model of a birth cohort screening program for hepatitis C virus. Hepatology, 2012, 55, 1344-1355.	10.6	102

#	ARTICLE	IF	PR CITATIONS
415	The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology</i> , 2012, 55, 2005-2023.	10.6	3,167
416	Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). <i>Brain and Behavior</i> , 2012, 2, 525-531.	2.5	12
417	The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. <i>Journal of Translational Medicine</i> , 2012, 10, .	6.6	22
418	Potential mechanisms underlying the associations between liver enzymes and risk for type 2 diabetes. <i>Hepatology</i> , 2012, 55, 968-970.	10.6	9
419	Anthropometric and Clinical Factors Associated with Mortality in Subjects with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2012, 58, 1132-1140.	2.3	61
420	Quality of Life in Cirrhosis. <i>Current Gastroenterology Reports</i> , 2012, 15, .	2.7	75
421	Telaprevir for Retreatment of HCV Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2417-2428.	43.7	1,478
422	Protein Pathway Activation Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV). <i>Journal of Proteome Research</i> , 2011, 10, 774-779.	3.5	10
423	Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 524-530.e1.	6.2	980
424	Depression in Patients with Nonalcoholic Fatty Liver Disease and Chronic Viral Hepatitis B and C. <i>Psychosomatics</i> , 2011, 52, 127-132.	3.0	132
425	Biomarkers for Non-invasive Diagnosis of Non-alcoholic Steatohepatitis. <i>Obesity Surgery</i> , 2011, 21, 1318-1318.	2.4	0
426	Association of Obestatin, Ghrelin, and Inflammatory Cytokines in Obese Patients with Non-alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2011, 21, 1750-1757.	2.4	55
427	Non-Invasive markers for hepatic fibrosis. <i>BMC Gastroenterology</i> , 2011, 11, .	2.4	248
428	Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States. <i>Hepatology</i> , 2011, 53, 737-745.	10.6	85
429	Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. <i>Hepatology</i> , 2011, 53, 1874-1882.	10.6	574
430	Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population. <i>Hepatology</i> , 2011, 54, 1167-1178.	10.6	38
431	Novel treatment strategies for patients with nonalcoholic fatty liver disease. <i>Clinical Investigation</i> , 2011, 1, 229-239.	0.3	7
432	Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 479-484.	1.8	67

#	ARTICLE	IF	PR CITATIONS
433	Hepatic Gene Expression of Caucasian and African-American Patients with Obesity-Related Non-Alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2010, 20, 640-650.	2.4	55
434	Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. <i>BMC Molecular Biology</i> , 2010, 11, 39.	4.1	99
435	A Methodology for Successfully Producing Global Translations of Patient Reported Outcome Measures for Use in Multiple Countries. <i>Value in Health</i> , 2010, 13, 128-131.	2.0	31
436	Response to the Letter from Ms. Tamzin Furtado. <i>Value in Health</i> , 2010, 13, 508.	2.0	1
437	Non-Alcoholic Fatty Liver Disease After Liver Transplantation: A Case of Nurture and Nature. <i>American Journal of Gastroenterology</i> , 2010, 105, 621-623.	0.7	13
438	Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. <i>Gut</i> , 2010, 59, 1410-1415.	21.2	277
439	Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality From Liver Cancer in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 718-723.	6.2	36
440	Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 1017-1029.	6.2	151
441	Phosphoproteomic Biomarkers Predicting Histologic Nonalcoholic Steatohepatitis and Fibrosis. <i>Journal of Proteome Research</i> , 2010, 9, 3218-3224.	3.5	25
442	Review: Treatment options for nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 121-137.	3.5	121
443	Hepatitis C and metabolic syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 209-215.	3.1	0
444	A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis. <i>Obesity Surgery</i> , 2010, 21, 431-439.	2.4	148
445	Treatment regimens for non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2009, 8, S51-S59.	1.6	42
446	Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. <i>Hepatology</i> , 2009, 49, 763-774.	10.6	40
447	Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. <i>Liver International</i> , 2009, 29, 3-12.	4.1	53
448	Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. <i>Liver International</i> , 2009, 29, 1403-1412.	4.1	15
449	Expression of Cytokine Signaling Genes in Morbidly Obese Patients with Non-Alcoholic Steatohepatitis and Hepatic Fibrosis. <i>Obesity Surgery</i> , 2009, 19, 617-624.	2.4	47
450	Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 234-238.	6.2	682

#	ARTICLE	IF	PR CITATIONS
451	Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1224-1229.e2.	6.2	308
452	Nonalcoholic Fatty Liver Disease: A Practical Approach to Evaluation and Management. <i>Clinics in Liver Disease</i> , 2009, 13, 249-266.	3.7	58
453	Monoclonal and Polyclonal Antibodies Against the HCV Envelope Proteins. <i>Clinics in Liver Disease</i> , 2009, 13, 477-486.	3.7	6
454	Hepatic Stellate Cell and Myofibroblast-Like Cell Gene Expression in the Explanted Cirrhotic Livers of Patients Undergoing Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2009, 55, 496-504.	2.3	4
455	The factorial structure of the Chronic Liver Disease Questionnaire (CLDQ). <i>Quality of Life Research</i> , 2008, 17, 575-584.	2.1	50
456	A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH). <i>Obesity Surgery</i> , 2008, 18, 1430-1437.	2.4	263
457	Metabolic Syndrome after Laparoscopic Bariatric Surgery. <i>Obesity Surgery</i> , 2008, 18, 1278-1286.	2.4	35
458	Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. <i>Liver Transplantation</i> , 2008, 14, 321-326.	2.6	62
459	Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study. <i>American Journal of Gastroenterology</i> , 2008, 103, 2263-2271.	0.7	309
460	Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2008, 49, 608-612.	3.6	608
461	Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 207-215.	2.5	21
462	Effects of Weight Loss on Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2008, 28, 427-433.	3.4	68
463	Nutritional Assessments of Patients with Non-alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2008, 20, 154-160.	2.4	53
464	Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. <i>Cleveland Clinic Journal of Medicine</i> , 2008, 75, 721-728.	1.4	295
465	Evaluation and management of obesity-related nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 432-441.	4.3	90
466	Anger Experiences Among Hepatitis C Patients: Relationship to Depressive Symptoms and Health-Related Quality of Life. <i>Psychosomatics</i> , 2007, 48, 223-229.	3.0	37
467	Epidemiology and Natural History of NAFLD and NASH. <i>Clinics in Liver Disease</i> , 2007, 11, 1-16.	3.7	406
468	Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 195-205.	3.2	14

#	ARTICLE	IF	PR CITATIONS
469	The Role of Genomics and Proteomics: Technologies in Studying Non-alcoholic Fatty Liver Disease. Clinics in Liver Disease, 2007, 11, 209-220.	3.7	29
470	Pathologic Assessment of Non-alcoholic Fatty Liver Disease. Clinics in Liver Disease, 2007, 11, 17-23.	3.7	67
471	The effects of HCV infection and management on health-related quality of life. Hepatology, 2007, 45, 806-816.	10.6	167
472	A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology, 2007, 46, 166-172.	10.6	48
473	Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: The hepatitis B quality of life instrument, version 1.0. Hepatology, 2007, 46, 113-121.	10.6	75
474	Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver International, 2007, 27, 607-611.	4.1	107
475	Health-related quality of life in patients with chronic hepatitis B. Liver International, 2007, 27, 1119-1125.	4.1	71
476	Fatigue and Health-Related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection. Digestive Diseases and Sciences, 2007, 52, 2531-2539.	2.3	145
477	Gene Expression Patterns in Hepatic Tissue and Visceral Adipose Tissue of Patients with Non-Alcoholic Fatty Liver Disease. Obesity Surgery, 2007, 17, 1111-1118.	2.4	55
478	Depression, anemia and health-related quality of life in chronic hepatitis C. Journal of Hepatology, 2006, 44, 491-498.	3.6	130
479	Gene Expression of Leptin, Resistin, and Adiponectin in the White Adipose Tissue of Obese Patients with Non-Alcoholic Fatty Liver Disease and Insulin Resistance. Obesity Surgery, 2006, 16, 1118-1125.	2.4	100
480	Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study. Liver Transplantation, 2006, 12, 1381-1389.	2.6	110
481	The Use of Growth Factors to Manage the Hematologic Side Effects of PEG-Interferon Alfa and Ribavirin. Journal of Clinical Gastroenterology, 2005, 39, S9-S13.	2.4	54
482	High Rates of Uninsured Among HCV-Positive Individuals. Journal of Clinical Gastroenterology, 2005, 39, 826-830.	2.4	32
483	Impact of Adherence on the Outcome of Antiviral Therapy for Chronic Hepatitis C. Journal of Clinical Gastroenterology, 2005, 39, S23-S27.	2.4	45
484	Obesity-related Differential Gene Expression in the Visceral Adipose Tissue. Obesity Surgery, 2005, 15, 758-765.	2.4	68
485	Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver International, 2005, 25, 760-771.	4.1	105
486	Microarray technology in the study of obesity and non-alcoholic fatty liver disease. Liver International, 2005, 25, 1091-1096.	4.1	15

#	ARTICLE	IF	PR CITATIONS
487	Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. <i>Hepatology</i> , 2005, 41, 790-800.	10.6	337
488	A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005, 42, 665-674.	10.6	223
489	MELD fails to measure quality of life in liver transplant candidates. <i>Liver Transplantation</i> , 2005, 11, 218-223.	2.6	117
490	Pegylated Interferon α -2b, Ribavirin and Amantadine for Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2005, 50, 970-975.	2.3	13
491	Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2005, 9, 617-634.	3.7	29
492	Interactions between non-alcoholic fatty liver disease and hepatitis C viral infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S253-S257.	2.7	3
493	Nonalcoholic steatohepatitis. <i>Current Treatment Options in Gastroenterology</i> , 2004, 7, 423-430.	0.9	2
494	Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. <i>Hepatology</i> , 2004, 40, 1450-1458.	10.6	136
495	Nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 262-265.	6.2	402
496	Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. <i>Human Pathology</i> , 2004, 35, 196-199.	2.4	145
497	Obesity and Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 705-709.	2.4	112
498	Nonalcoholic fatty liver disease and the epidemic of obesity.. <i>Cleveland Clinic Journal of Medicine</i> , 2004, 71, 657-664.	1.4	32
499	Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. <i>Hepatology</i> , 2003, 38, 75-85.	10.6	537
500	Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003, 98, 2060-2063.	0.7	167
501	The utility of radiological imaging in nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2002, 123, 745-750.	1.0	1,883
502	The impact of liver disease on health-related quality of life: A review of the literature. <i>Current Gastroenterology Reports</i> , 2002, 4, 79-83.	2.7	45
503	Nonalcoholic fatty liver disease: An agenda for clinical research. <i>Hepatology</i> , 2002, 35, 746-752.	10.6	219
504	Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. <i>American Journal of Medicine</i> , 2001, 111, 614-621.	2.3	68

#	ARTICLE	IF	PR CITATIONS
505	Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. <i>Liver</i> , 2001, 21, 266-271.	0.0	139
506	The role of liver biopsy in chronic hepatitis C. <i>Hepatology</i> , 2001, 33, 196-200.	10.6	212
507	Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. <i>Liver Transplantation</i> , 2001, 7, 797-801.	2.6	238
508	Health-related quality of life in chronic liver disease: the impact of type and severity of disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 2199-2205.	0.7	298
509	Assessment of Utilities and Health-Related Quality of Life in Patients With Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 579-583.	0.7	139
510	Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes. <i>Seminars in Liver Disease</i> , 2001, 21, 017-026.	3.4	536
511	A pharmaco-economic appraisal of therapies for hepatitis B and C. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 205-211.	2.2	1
512	Hepatitis C, interferon alfa, and depression. <i>Hepatology</i> , 2000, 31, 1207-1211.	10.6	200
513	Impact of liver transplantation on health-related quality of life. <i>Liver Transplantation</i> , 2000, 6, 779-783.	2.6	95
514	Cholestatic Liver Diseases and Health-Related Quality of Life. <i>American Journal of Gastroenterology</i> , 2000, 95, 497-502.	0.7	145
515	Immunogenicity of Hepatitis A Vaccine in Decompensated Liver Disease. <i>American Journal of Gastroenterology</i> , 1999, 94, 1601-1604.	0.7	94
516	Nonalcoholic fatty liver disease. <i>Current Gastroenterology Reports</i> , 1999, 1, 57-62.	2.7	29
517	Hepatic iron and nonalcoholic fatty liver disease. <i>Hepatology</i> , 1999, 30, 847-850.	10.6	219
518	Evidence-based medicine: A method for solving clinical problems in hepatology. <i>Hepatology</i> , 1999, 30, 829-832.	10.6	13
519	Cost effectiveness of interferon α 2b combined with ribavirin for the treatment of chronic hepatitis C. <i>Hepatology</i> , 1999, 30, 1318-1324.	10.6	159
520	Outcome of De Novo hepatitis C virus infection in heart transplant recipients. <i>Hepatology</i> , 1999, 30, 1293-1298.	10.6	82
521	CHRONIC VIRAL HEPATITIS IN RENAL TRANSPLANT RECIPIENTS WITH ALLOGRAFTS FUNCTIONING FOR MORE THAN 20 YEARS ^{1,2} . <i>Transplantation</i> , 1999, 67, 272-275.	1.2	65
522	Agreement in Pathologic Interpretation of Liver Biopsy Specimens in Posttransplant Hepatitis C Infection. <i>Archives of Pathology and Laboratory Medicine</i> , 1999, 123, 143-145.	2.5	15

#	ARTICLE	IF	PR CITATIONS
523	Reply to Bailly, et al. <i>Clinical Infectious Diseases</i> , 0, , .	5.4	1
524	Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 0, , .	2.3	3